Crocs - CROX Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crocs in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CROX shares.
View CROX analyst ratings or view top-rated stocks.

10 brokers have issued 12 month price targets for Crocs' stock. Their CROX share price forecasts range from $54.00 to $150.00. On average, they predict the company's stock price to reach $90.57 in the next year. This suggests that the stock has a possible downside of 6.2%.
View analysts price targets for CROX or view top-rated stocks among Wall Street analysts.

Crocs' stock was trading at $128.22 at the beginning of the year. Since then, CROX shares have decreased by 24.7% and is now trading at $96.53.
View the best growth stocks for 2022 here.

Crocs saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 5,130,000 shares, an increase of 13.0% from the October 31st total of 4,540,000 shares. Based on an average daily volume of 1,740,000 shares, the short-interest ratio is presently 2.9 days. Currently, 8.7% of the company's stock are sold short.
View Crocs' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our CROX earnings forecast.

Crocs, Inc. (NASDAQ:CROX) posted its quarterly earnings results on Thursday, November, 3rd. The textile maker reported $2.97 EPS for the quarter, topping analysts' consensus estimates of $2.58 by $0.39. The textile maker had revenue of $985.09 million for the quarter, compared to analyst estimates of $941.88 million. Crocs had a trailing twelve-month return on equity of 172.58% and a net margin of 17.43%.

Crocs issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of $9.95-$10.30 for the period, compared to the consensus estimate of $10.09. The company issued revenue guidance of $3.46 billion-$3.52 billion, compared to the consensus revenue estimate of $3.46 billion.

67 employees have rated Crocs Chief Executive Officer Andrew Rees on Glassdoor.com. Andrew Rees has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crocs investors own include Skyworks Solutions (SWKS), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), Bank of America (BAC), Denbury Resources (DNR), Cisco Systems (CSCO), Micron Technology (MU), AT&T (T) and Tesla (TSLA).

Crocs trades on the NASDAQ under the ticker symbol "CROX."

Crocs' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.58%), Vanguard Group Inc. (9.20%), State Street Corp (3.15%), Marshall Wace LLP (2.78%), Samlyn Capital LLC (1.70%) and Polaris Capital Management LLC (1.19%). Insiders that own company stock include Andrew Rees, Anne Mehlman, Beth J Kaplan, Daniel P Hart, Doreen A Wright, Douglas J Treff, Elaine L Boltz, Ian Bickley, Michelle Poole, Ronald Frasch, Shannon Sisler and Thomas J Smach.
View institutional ownership trends.

Shares of CROX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CROX stock can currently be purchased for approximately $96.53.

Crocs (NASDAQ:CROX) has a market capitalization of $5.96 billion and generates $2.31 billion in revenue each year. The textile maker earns $725.69 million in net income (profit) each year or $9.06 on an earnings per share basis.

The company employs 5,770 workers across the globe.

Crocs' mailing address is 13601 Via Varra, Broomfield CO, 80020. The official website for the company is www.crocs.com. The textile maker can be reached via phone at (303) 848-7000, via email at brendon.frey@icrinc.com, or via fax at 303-468-4266.